|
|
Volumn 14, Issue 3, 2002, Pages 276-280
|
|
Drug development in rheumatoid arthritis
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIRHEUMATIC AGENT;
CELECOXIB;
ETANERCEPT;
INFLIXIMAB;
LEFLUNOMIDE;
METHOTREXATE;
NONSTEROID ANTIINFLAMMATORY AGENT;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
ROFECOXIB;
VALDECOXIB;
BONE EROSION;
CLINICAL TRIAL;
DEVICE;
DISABILITY;
DRUG APPROVAL;
DRUG DEVELOPMENT;
DRUG LABELING;
DRUG RESPONSE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
POLICY;
PRIORITY JOURNAL;
REMISSION;
REVIEW;
RHEUMATOID ARTHRITIS;
RISK BENEFIT ANALYSIS;
UNITED STATES;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
DRUG INDUSTRY;
DRUG LABELING;
HUMANS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0036229807
PISSN: 10408711
EISSN: None
Source Type: Journal
DOI: 10.1097/00002281-200205000-00014 Document Type: Review |
|
Times cited : (1)
|
|
References (11)
|
